HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma.

AbstractBACKGROUND:
Drug resistance is a primary hindrance for the efficiency of chemotherapy against osteosarcoma. Although chemotherapy has improved the prognosis of osteosarcoma patients dramatically after introduction of neo-adjuvant therapy in the early 1980's, the outcome has since reached plateau at approximately 70% for 5 year survival. The remaining 30% of the patients eventually develop resistance to multiple types of chemotherapy. In order to overcome both the dose-limiting side effects of conventional chemotherapeutic agents and the therapeutic failure incurred from multidrug resistant (MDR) tumor cells, we explored the possibility of loading doxorubicin onto biocompatible, lipid-modified dextran-based polymeric nanoparticles and evaluated the efficacy.
METHODS:
Doxorubicin was loaded onto a lipid-modified dextran based polymeric nano-system. The effect of various concentrations of doxorubicin alone or nanoparticle loaded doxorubicin on KHOS, KHOSR2, U-2OS, and U-2OSR2 cells was analyzed. Effects on drug retention, immunofluorescence, Pgp expression, and induction of apoptosis were also analyzed.
RESULTS:
Dextran nanoparticles loaded with doxorubicin had a curative effect on multidrug resistant osteosarcoma cell lines by increasing the amount of drug accumulation in the nucleus via Pgp independent pathway. Nanoparticles loaded with doxorubicin also showed increased apoptosis in osteosarcoma cells as compared with doxorubicin alone.
CONCLUSION:
Lipid-modified dextran nanoparticles loaded with doxorubicin showed pronounced anti-proliferative effects against osteosarcoma cell lines. These findings may lead to new treatment options for MDR osteosarcoma.
AuthorsMichiro Susa, Arun K Iyer, Keinosuke Ryu, Francis J Hornicek, Henry Mankin, Mansoor M Amiji, Zhenfeng Duan
JournalBMC cancer (BMC Cancer) Vol. 9 Pg. 399 (Nov 16 2009) ISSN: 1471-2407 [Electronic] England
PMID19917123 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Dextrans
  • Drug Carriers
  • Polymers
  • Doxorubicin
Topics
  • Antineoplastic Agents (administration & dosage)
  • Apoptosis (drug effects)
  • Blotting, Western
  • Bone Neoplasms (drug therapy)
  • Cell Line, Tumor
  • Dextrans (pharmacology)
  • Doxorubicin (administration & dosage)
  • Drug Carriers (pharmacology)
  • Drug Delivery Systems (methods)
  • Drug Resistance, Neoplasm (drug effects)
  • Flow Cytometry
  • Humans
  • Microscopy, Fluorescence
  • Nanoparticles (therapeutic use)
  • Osteosarcoma (drug therapy)
  • Polymers (pharmacokinetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: